Eli Lilly and Novo Nordisk will lower prices for GLP-1 drugs, aligning with new drug pricing initiatives and Medicare Part D pilot coverage starting April 2026. Lilly's Zepbound and orforglipron will ...

Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...

Direct-to-consumer drug sales aim to simplify pricing and increase transparency by allowing patients to buy directly from ...

The national five-year survival rate for lung cancer has climbed to nearly 30%, up from 18% from eight years ago, according to the American Lung Association.

Melissa Hanna, J.D., MBA, co-founder and CEO of Mahmee, was one of Managed Healthcare Executive’s 2021 Emerging Leaders in Healthcare. Four years later, she continues to lead the company as it expands ...

AI's role in cancer detection has evolved from Wolfe's 1970s mammographic pattern research to modern predictive models like Mirai and CHIEF. Interreader variability and regulatory challenges persist, ...